GEP20002141B - Use of 2-Phenyl-1, 2-Benzisoselenazol-3(2H)-One for Prevention and/or Treatment of Dementia, a Pharmaceutical Composition for Prevention and/or Treatment of the Alzheimer’s Disease - Google Patents

Use of 2-Phenyl-1, 2-Benzisoselenazol-3(2H)-One for Prevention and/or Treatment of Dementia, a Pharmaceutical Composition for Prevention and/or Treatment of the Alzheimer’s Disease

Info

Publication number
GEP20002141B
GEP20002141B GEAP19974539A GEAP1997004539A GEP20002141B GE P20002141 B GEP20002141 B GE P20002141B GE AP19974539 A GEAP19974539 A GE AP19974539A GE AP1997004539 A GEAP1997004539 A GE AP1997004539A GE P20002141 B GEP20002141 B GE P20002141B
Authority
GE
Georgia
Prior art keywords
prevention
treatment
dementia
benzisoselenazol
alzheimer
Prior art date
Application number
GEAP19974539A
Inventor
Hiroyuki Masayasu
Kazuhiro Abeyama
Ikuo Maruyama
Original Assignee
A Nattermann & Cie Gmbh De
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A Nattermann & Cie Gmbh De filed Critical A Nattermann & Cie Gmbh De
Publication of GEP20002141B publication Critical patent/GEP20002141B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1. Technical Result Increase in efficiency for prevention and/or treatment of dementia. 2. Essence 2-phenyl-1,2-benzisoselenazol-3(2H)-one a suitable medical agent of dementia, in particular for prevention and/or treatment of dementia Alzheimer’s decease. A pharmaceutical composition for prevention and/or treatment of the Alzheimer’s disease comprises in the form of active compound 2-phrnil-1,2-, 2-Benzisoselenazol-3(2H)-one in the pharmaceutical effective amount. 3. Field of Application Medicine. Tables: 2
GEAP19974539A 1996-08-27 1997-04-07 Use of 2-Phenyl-1, 2-Benzisoselenazol-3(2H)-One for Prevention and/or Treatment of Dementia, a Pharmaceutical Composition for Prevention and/or Treatment of the Alzheimer’s Disease GEP20002141B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP225512 1996-08-27

Publications (1)

Publication Number Publication Date
GEP20002141B true GEP20002141B (en) 2000-06-25

Family

ID=82493847

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP19974539A GEP20002141B (en) 1996-08-27 1997-04-07 Use of 2-Phenyl-1, 2-Benzisoselenazol-3(2H)-One for Prevention and/or Treatment of Dementia, a Pharmaceutical Composition for Prevention and/or Treatment of the Alzheimer’s Disease

Country Status (1)

Country Link
GE (1) GEP20002141B (en)

Similar Documents

Publication Publication Date Title
GR1003011B (en) Novel formulation
BG105435A (en) Stable liquid formulations of botulinum toxin
MY132705A (en) Novel compounds with analgesic effect
TR199801180T2 (en) New compounds with analgesic effect.
MY119403A (en) Novel compounds with analgesic effect.
GEP20022783B (en) Method of Preventing and Delaying Onset of Alzheimer's Disease and Composition Therefor
TW250435B (en)
GEP20032869B (en) Alpha -Ketoamide Inhibitors of 20S Proteasome, Pharmaceutical Preparations Containing the Same and Methods for Treatment
GEP20032896B (en) 4-Aminothiazole Derivatives, Containing Them Pharmaceutical Compositions Inhibiting Cyclin-Dependent Kinases and Methods for Treatment
IS1907B (en) Use of the chelating agent clioquinol in the preparation of a pharmaceutical composition for the treatment of Alzheimer's disease
GB0005251D0 (en) Therapeutic compounds
MY164077A (en) Compositions and uses of et743 for treating cancer
MX9708800A (en) Bicyclic-aromatic compounds.
DK0629400T3 (en) Idebenone-containing preparations for the treatment of Alzheimer's disease
MX9708803A (en) Diaromatic propynyl or dienyl compounds.
PL338673A1 (en) Application of fanquinone in treating alzheimer disease
PL346767A1 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
EP0744176A3 (en) Methods for inhibiting bone loss
GEP20043231B (en) Resorcinol Composition
GEP20002141B (en) Use of 2-Phenyl-1, 2-Benzisoselenazol-3(2H)-One for Prevention and/or Treatment of Dementia, a Pharmaceutical Composition for Prevention and/or Treatment of the Alzheimer’s Disease
ATE106732T1 (en) MEDICATION PREPARATION CONTAINING STIGMASTA-4-EN-3-ONE AND USE THEREOF.
HU9802896D0 (en) Optically active piperidinoalkyl-4h-1,2,4-oxadiazine derivative, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
GEP20002177B (en) Ointment “Levaskani” for Treatment of Wounds and Burns
ES2159479A1 (en) Set of therapeutic indazols consists of inhibitors of cyclooxygenase combating eg. inflammation and Alzheimer's disease
IT1264428B1 (en) Pharmaceutical compositions for the treatment of psoriasis